Ma et al. [4] reported that PHLDA3 protein overexpression in prostate cancer suppresses β-catenin activity by decreasing phosphorylated GSK3β, promoting β-catenin degradation and downregulating Wnt target gene expression. The gene discussed is PHLDA3; the disease is prostate carcinoma.